首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL5 |
| Uniprot No | P42830 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-114aa |
| 氨基酸序列 | AAVLRELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEI CLDPEAPFLKKVIQKILDGGNKEN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL5重组蛋白的3篇参考文献，简明列举如下：
---
1. **文献名称**: *CXCL5 promotes prostate cancer progression via neutrophil activation and immunosuppression*
**作者**: Wang G, et al.
**摘要**: 研究利用重组CXCL5蛋白体外处理中性粒细胞，发现其通过激活STAT3信号通路促进前列腺癌的免疫抑制微环境，增强肿瘤侵袭和转移。
---
2. **文献名称**: *Recombinant CXCL5 induces inflammatory responses and enhances mucosal barrier injury in a murine colitis model*
**作者**: Zhang Y, et al.
**摘要**: 在小鼠结肠炎模型中注射重组CXCL5蛋白，结果显示其通过招募中性粒细胞和上调IL-6表达，加剧肠道屏障损伤和炎症反应。
---
3. **文献名称**: *CXCL5-mediated neutrophil recruitment promotes angiogenesis in breast cancer*
**作者**: Li J, et al.
**摘要**: 实验通过重组CXCL5蛋白刺激乳腺癌细胞，证实其通过诱导中性粒细胞分泌VEGF，促进肿瘤血管生成和生长，机制涉及PI3K/AKT通路激活。
---
以上文献均聚焦CXCL5重组蛋白在疾病模型中的功能机制，涵盖肿瘤微环境调控、炎症反应及血管生成等领域。
CXCL5 (C-X-C motif chemokine ligand 5), also known as epithelial-derived neutrophil-activating peptide 78 (ENA-78), is a small secretory protein belonging to the CXC chemokine family. It plays a pivotal role in mediating immune responses by recruiting and activating neutrophils via binding to its receptor CXCR2. CXCL5 is constitutively expressed by various cells, including epithelial cells, macrophages, and endothelial cells, and its production is upregulated by proinflammatory stimuli such as TNF-α, IL-1β, or bacterial lipopolysaccharides (LPS). Structurally, it contains conserved cysteine residues forming a characteristic three-dimensional fold critical for receptor interaction.
Recombinant CXCL5 protein is produced using expression systems like *E. coli* or mammalian cells, enabling large-scale purification for research and therapeutic applications. The recombinant form retains biological activity, including chemotactic properties, and is widely used to study neutrophil migration, inflammation mechanisms, and tissue repair processes. Its role extends beyond immunity; aberrant CXCL5 expression is linked to pathological conditions, including chronic inflammatory diseases (e.g., rheumatoid arthritis), cancer progression (promoting angiogenesis and metastasis), and severe infections. In cancer biology, CXCL5 is implicated in shaping the tumor microenvironment, enhancing immunosuppression, and fostering resistance to therapies.
Researchers utilize recombinant CXCL5 in *in vitro* assays (e.g., chemotaxis chambers) and *in vivo* models to explore its functions or screen inhibitors. Quality assessments often involve SDS-PAGE, Western blotting, and functional validation via neutrophil migration assays. Current studies also investigate CXCL5 as a potential biomarker or therapeutic target, particularly in diseases with dysregulated neutrophil activity. However, its dual pro-inflammatory and tissue-repair roles necessitate context-specific evaluation in therapeutic strategies.
×
